Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits

被引:17
作者
Ernofsson, M
Thelin, S
Siegbahn, A
机构
[1] UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT CARDIOVASC THORAC SURG,S-75185 UPPSALA,SWEDEN
来源
SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 1995年 / 29卷 / 04期
关键词
cardiopulmonary bypass; heparin coating; biocompatible surfaces; thrombin generation; thrombin-antithrombin III complex; prothrombin fragment 1+2;
D O I
10.3109/14017439509107224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For quantitative comparison of thrombin generation during cardiopulmonary bypass (CPB) with heparin-coated vs conventional CPB circuits, thrombin-antithrombin III complex (TAT) and prothrombin fragment 1+2 (F-1+2) were analyzed in 20 patients undergoing combined heart valve surgery and coronary artery bypass grafting (CABG), in ten cases with heparin-coated circuits (COMB-HC) and in ten with standard circuits (COMB-C). Extensive thrombin generation was found in both groups, with maximal TAT and F-1+2 levels at the end of CPB. Of 15 operations with only CABG, seven were performed with heparin-coated circuits and heparin dose 40% of normal (CABG-HC), and eight with standard circuits and normal heparin doses (CABG-C). TAT was maximal at the end of CPB and F-1+2 peaked 3 hours after protamine injection. At the end of CPB both levels were significantly higher in the CABG-HC than in the CABG-C group, though thrombin generation was less than in the COMB groups. The abundant thrombin generation during CPB thus was much more pronounced during complex operations. Use of heparin-coated circuits did not reduce thrombin generation, which was increased by 60% reduction of the systemic heparin dose. The clinical implications are still unknown, as no complications were observed.
引用
收藏
页码:157 / 165
页数:9
相关论文
共 37 条
[1]   BINDING OF THROMBIN TO SUBENDOTHELIAL EXTRACELLULAR-MATRIX - PROTECTION AND EXPRESSION OF FUNCTIONAL-PROPERTIES [J].
BARSHAVIT, R ;
ELDOR, A ;
VLODAVSKY, I .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1096-1104
[2]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[3]  
BOISCLAIR MD, 1993, THROMB HAEMOSTASIS, V70, P253
[4]   DECREASED BLOOD-LOSS AFTER CARDIOPULMONARY BYPASS USING HEPARIN-COATED CIRCUIT AND 50-PERCENT REDUCTION OF HEPARIN DOSE [J].
BOROWIEC, J ;
THELIN, S ;
BAGGE, L ;
HULTMAN, J ;
HANSSON, HE .
SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1992, 26 (03) :177-185
[5]  
BOROWIEC J, 1992, J THORAC CARDIOV SUR, V104, P642
[6]   HEPARIN-COATED CARDIOPULMONARY BYPASS CIRCUITS AND 25-PERCENT REDUCTION OF HEPARIN DOSE IN CORONARY-ARTERY SURGERY - A CLINICAL-STUDY [J].
BOROWIEC, J ;
THELIN, S ;
BAGGE, L ;
VANDERLINDEN, J ;
THORNO, E ;
HANSSON, HE .
UPSALA JOURNAL OF MEDICAL SCIENCES, 1992, 97 (01) :55-66
[7]  
BRISTER SJ, 1993, THROMB HAEMOSTASIS, V70, P259
[8]   COMPLEMENT ACTIVATION DURING CARDIOPULMONARY BYPASS - EVIDENCE FOR GENERATION OF C3A AND C5A ANAPHYLATOXINS [J].
CHENOWETH, DE ;
COOPER, SW ;
HUGLI, TE ;
STEWART, RW ;
BLACKSTONE, EH ;
KIRKLIN, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (09) :497-503
[9]  
Conover WJ, 1980, PRACTICAL NONPARAMET, P299
[10]  
ELGUE G, 1993, THROMB HAEMOSTASIS, V70, P289